Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, has appointed Dominik Kugelstadt head of clinical and commercial manufacturing of the Laupheim site, and will serve as a member of the Laupheim leadership team.

Kugelstadt is responsible for all areas of production and reports to Laupheim’s site head. With his extensive experience in the manufacture of complex biologics and comprehensive knowledge of production management, Kugelstadt will play a leading role in ensuring the quality of Rentschler Biopharma’s service offering and expanding its portfolio.

Kugelstadt has more than 13 years of management experience in biopharmaceutical manufacturing. Most recently, he was head of Sanofi’s Mammalian Launch Plant, a manufacturing facility focused on the production of antibodies for Phase III clinical development and commercial launch. In this role, he was responsible for all aspects of production, including operational manufacturing, infrastructure, validation, supply chain and plant expansion, as well as audits and representing the company to regulatory authorities and other stakeholders. Prior to Sanofi, he worked for several years at Genzyme Virotech (later Sekisui Virotech).

“I am very pleased to welcome Dominik to our team,” said Christiane Bardroff, COO of Rentschler Biopharma. “As an experienced manufacturing executive, he knows our core business well and brings impressively broad expertise in production, that he will apply in leading our manufacturing department in Laupheim. He shares our focus on quality and will leverage his multifaceted profile and expertise to play a key role in continuing to sustainably create value for our clients.”

Dominik Kugelstadt said, “The combination of tradition and sustainability, along with the diversity of its projects, make Rentschler Biopharma a truly attractive place to work. I look forward, along with our talented and motivated team, to bringing solutions to existing and new clients, as we work together to bring novel biopharmaceuticals to help or even cure patients with serious and life-threatening diseases.”